Vianovatx
1 known investors
Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections. The company focuses on infections with high prevalence and severe illness potential, serving patients with unmet treatment needs across multiple viral categories.
BiotechDigital HealthMedical Devices